163 related articles for article (PubMed ID: 32094096)
1. The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study.
Zgheib NK; Alameddine R; Massoud R; Nasr R; Zahreddine A; El Cheikh J; Mahfouz R; Bazarbachi A
Curr Res Transl Med; 2020 Apr; 68(2):51-58. PubMed ID: 32094096
[TBL] [Abstract][Full Text] [Related]
2. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.
García M; Macías RM; Cubero JJ; Benítez J; Caravaca F; Gervasini G
Eur J Clin Pharmacol; 2013 Mar; 69(3):385-93. PubMed ID: 22886152
[TBL] [Abstract][Full Text] [Related]
4. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
[TBL] [Abstract][Full Text] [Related]
5. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
Atiq F; Hameli E; Broers AEC; Doorduijn JK; Van Gelder T; Andrews LM; Koch BCP; Versmissen J; de Winter BCM
Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
[TBL] [Abstract][Full Text] [Related]
6. Effect of cyclosporine a and polymorphisms in
Zeng G; Shi L; Li H; Wang L; Zhu M; Luo J; Zhang Z
Xenobiotica; 2020 May; 50(5):614-619. PubMed ID: 31573401
[TBL] [Abstract][Full Text] [Related]
7. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
[TBL] [Abstract][Full Text] [Related]
9. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
10. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
[TBL] [Abstract][Full Text] [Related]
11. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing.
Patel JN; Robinson M; Morris SA; Jandrisevits E; Lopes KE; Hamilton A; Steuerwald N; Druhan LJ; Avalos B; Copelan E; Ghosh N; Grunwald MR
Pharmacogenomics J; 2023 Nov; 23(6):201-209. PubMed ID: 37925536
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
Haufroid V; Mourad M; Van Kerckhove V; Wawrzyniak J; De Meyer M; Eddour DC; Malaise J; Lison D; Squifflet JP; Wallemacq P
Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
[TBL] [Abstract][Full Text] [Related]
15. Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants.
Nara M; Takahashi N; Miura M; Niioka T; Kagaya H; Fujishima N; Saitoh H; Kameoka Y; Tagawa H; Hirokawa M; Sawada K
Eur J Clin Pharmacol; 2013 Jun; 69(6):1321-9. PubMed ID: 23354810
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
17. Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation.
Kikuchi T; Mori T; Yamane A; Kato J; Kohashi S; Okamoto S
Clin Transplant; 2012; 26(5):E544-8. PubMed ID: 23061764
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients.
Hamadeh IS; Zhang Q; Steuerwald N; Hamilton A; Druhan LJ; McSwain M; Diez Y; Rusin S; Han Y; Symanowski J; Gerber J; Grunwald MR; Ghosh N; Plesca D; Arnall J; Trivedi J; Avalos B; Copelan E; Patel JN
Biol Blood Marrow Transplant; 2019 Apr; 25(4):656-663. PubMed ID: 30597277
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic effect of voriconazole on cyclosporine in the treatment of aspergillosis after renal transplantation.
Park SJ; Song IS; Kang SW; Joo H; Kim TH; Yoon YC; Kim E; Choi YL; Shin JG; Son JH; Kim YH
Clin Nephrol; 2012 Nov; 78(5):412-8. PubMed ID: 23084335
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
